Cookies disclaimer

I agree Our site saves small pieces of text information (cookies) on your device in order to deliver better content and for statistical purposes. You can disable the usage of cookies by changing the settings of your browser. By browsing our website without changing the browser settings you grant us permission to store that information on your device.

Current Filters

Currency:
GBP
Recipients:
Volunteering Matters
The Royal British Legion
University of Cambridge

Filter By

Recipient Organizations (clear)
University of Oxford (1,569) University of Cambridge (1,282) University College London (1,143) Imperial College London (748) University of Edinburgh (718) Guy's and St Thomas' NHS Foundation Trust (565) King's College London (519) University of Manchester (443) University of Bristol (420) London School of Hygiene & Tropical Medicine (391) University of Glasgow (335) University of Dundee (312) University of Liverpool (307) Newcastle University (299) The Royal British Legion (299) University of Birmingham (298) Cardiff University (259) University of Leeds (235) King's College London (217) Queen Mary University of London (190) University of Warwick (182) University of York (177) Liverpool School of Tropical Medicine (173) University of Nottingham (173) University of Sheffield (171) Merched Y Wawr (159) University of Exeter (153) University of Leicester (149) Barnardo's (135) University of Southampton (125) The Scout Association (120) The Guide Association (119) Alzheimer's Society (112) University College Dublin (108) University of Aberdeen (107) Church of England Children's Society (104) Institute of Cancer Research (100) Birkbeck University of London (96) The National Trust for Places of Historic Interest or Natural Beauty (93) Cruse Bereavement Care (90) Queen's University Belfast (89) University of Sussex (88) St George's University of London (87) The National Childbirth Trust (86) Wellcome Trust Sanger Institute (86) Education Services - Headquarters (85) Volunteering Matters (83) University of St Andrews (78) Medical Research Council (73) National University of Ireland Galway (72) See Less

Results

LifeLines 20 Apr 2016

This is the expansion of a project supporting volunteers aged 50 plus to run activities for vulnerable older people to improve health and well-being. These have previously included art classes, creative writing, yoga and computer club. The group will expand across the city, recruiting more volunteers, supporting more than 800 new people and establishing a Men’s Network to encourage older men to socialise regularly. It will also extend its HealthLink scheme to help older people get to medical appointments.

Kilkeel RBL - Saving Our Community Venue 22 Oct 2015

The group is a community and voluntary based organisation providing a range of services and activities to the local community. They received a grant of £10,000 to make improvements to their venue so that it can be used for more classes and activities.

Grant to Royal British Legion Tipton Branch 19 May 2016

Remembering Tipton's World War One Heroes

Grant awarded to The Royal British Legion (Forest Hall) Branch And Club (Tyne & Wear) 20 Nov 1998

Towards improving access and facilities for disabled people at the Forest Hall Ex-Servicemen's Institute.

Grant awarded to Community Service Volunteers (Training and Enterprise NE) (Tyne & Wear) 13 Jul 2004

To provide daycare services to older people living in high rise flats in Newcastle.

Translational Medicine and Therapeutics Programme at the University of Cambridge: 'Molecular imaging of glycosylation changes in Barrett's oesophagus to detect dysplasia: endoscopic and radiological applications.' 31 Aug 2012

To determine whether glycans can be used as molecular imaging targets. We hypothesise that labelled glycan can be detected endoscopically and thereby guide biopsies to macroscopically normal areas of dysplasia within Barrett’s oesophagus as prior to more generalized application in the aerodigestive tract.An in vivo endoscopic molecular imaging study using lectin-guided biopsies in the surveillance of BE will be completed as well as adapting a bioorthogonal chemistry approach from an animal model to label the human oesophageal glycome in human organ culture as a step towards to imaging of the human glycome without the application of lectins for imaging.

Amount: £182,345
Funder: The Wellcome Trust
Recipient: University of Cambridge

Translational Medicine and Therapeutics Programme at the University of Cambridge: 'Activating Akt mutations and metabolism: translational and therapeutic opportunities.' 21 May 2012

To elucidate the mechanisms by which the AKT2-E17K mutation affects the regulation of the downstream substrates involved in glucose and lipid metabolism in vitro approaches including western blotting, immunoprecipitation, quantitative PCR and confocal microscopy will be used. Complementary studies with AKT inhibitors will be performed and their effects on the above outcomes will be assessed. Transgenic mouse models of the Akt2-E17K and Akt1-E17K mutations have been obtained and detailed phenotyping of these mice will provide in vivo insights into the consequences of the E17K mutation as well as reveal important insights into the isoform specific functions of these enzymes. In addition, these mice will be used for pre-clinical studies investigating the clinical efficacy of compounds that impact upon AKT signalling. Collectively, the data collected from these studies will inform future clinical studies investigating the efficacy of AKT inhibitors in disease states characterised by hyperinsulinism.

Amount: £144,918
Funder: The Wellcome Trust
Recipient: University of Cambridge

Interdisciplinary Training Programme for Clinicians in Translational Medicine and Therapeutics at the University of Cambridge: Support for the 2012 MPhil Appointments. 31 Aug 2012

We propose an innovative training scheme for Translational Medicine and Therapeutics (TMAT) which builds on the exceptional conjunction on the Cambridge campus of leading scientists and clinical specialists, with an industrial research environment embraced both by international pharmaceutical and local biotech companies. Much of this is found under the same roof, the Addenbrookes Centre for Clinical Investigation (ACCI), with a track record of integrated training: academic with industrial, clinical with scientific, pharmacology & therapeutics with patient-based specialties. The novel TMAT programme will attract the brightest candidates at several levels of seniority, ranging from MB PhD students to clinical lecturers, some wishing translational skills in their chosen specialty, others not yet differentiated who may become future leaders and teachers of TMAT. Each trainee will have a customised programme. Part of this will be a bespoke, modular MSc modelled on the well-known small-group lectures and supervisions of the Cambridge final year undergraduate courses. However the centrepiece for most candidates will be a PhD including formal teaching in a wide range of translational and pharmacological skills, and a project which takes proof-of-concept studies in cell or animal systems forward to proof-of-concept studies in humans. We have assembled an outstanding faculty of PhD supervisors spanning a wide choice of skills and experience in basic and clinical science. All trainees will have the opportunity for hands-on exposure to the design and conduct of experimental medicine studies investigating the therapeutic potential of new drugs, in collaboration with our industrial partner, GlaxoSmithKline (GSK). Our product will be a new generation of clinician scientists with 360-degree vision of the complex landscape of modern therapeutic medicine, who can rise to the challenges and opportunities of 21st century drug development.

Amount: £18,531
Funder: The Wellcome Trust
Recipient: University of Cambridge

Training Programme in Translational Medicine and Therapeutics at the University of Cambridge: 'Novel therapeutics in multiple sclerosis and regulation of the immune system'. 17 Sep 2012

This project has two key goals: to investigate the role of IL7 and IL7R in the pathogenesis of multiple sclerosis and, in so doing, to educate a young physician about translational medicine. It is built upon the observations that IL7R is genetically associated with multiple sclerosis and that an antibody which antagonises IL7R ameliorated the animal model of multiple sclerosis by downregulating TH17 cells. The research question is: does antagonism of the IL7/IL7receptor pathway reduce disease activity in multiple sclerosis?The applicant will first investigate the in vitro consequences to lymphocyte biology of IL7R genotype; then explore the effect of this genotype on reconstitution of the lymphocyte repertoire therapeutic depletion. Then he will take part in a first-in-human anti-IL7R antibody trial in healthy individuals and people with multiple sclerosis. He will be involved in the design and execution of the clinical trial and the parallel laboratory studies.

Amount: £247,313
Funder: The Wellcome Trust
Recipient: University of Cambridge

Cambridge Stem Cell Institute. 17 Apr 2012

This proposal is to facilitate creation of a world-leading centre for fundamental and translational stem cell research. The Cambridge Stem Cell Institute (SCI) will build upon previous Wellcome Trust and Medical Research Council funding by drawing together 30 research teams into a cohesive centre. These groups will ultimately be co-located in a purpose-designed 8000m2 facility to be constructed on the Cambridge Biomedical Research Campus. Platform technologies supported by a Centre grant will en able SCI to recruit and retain the most talented investigators and empower them to make ground-breaking advances in understanding stem cells and their medical applications. Fundamental research will focus at the molecular level on mechanisms of self-renewal, commitment, differentiation and reprogramming. Functional studies will address the role of stem cells in development, repair, ageing, physiology and pathologies including cancer. Disease-specific induced pluripotent stem cells will be exploi ted to unravel mechanisms of cellular pathogenesis and define drug targets. Strategies to mobilise endogenous stem cells for regeneration will be evaluated in animal models and in the clinic as will approaches based on cell transplantation. The Institute will provide comprehensive training in embryonic and adult stem cell biology and will seek, and offer unique opportunities for, bioindustry interaction and collaboration.

Amount: £4,314,068
Funder: The Wellcome Trust
Recipient: University of Cambridge

Cambridge Stem Cell Institute Four year PhD studentships - Stem Cell Biology. 17 Apr 2012

This proposal is to facilitate creation of a world-leading centre for fundamental and translational stem cell research. The Cambridge Stem Cell Institute (SCI) will build upon previous Wellcome Trust and Medical Research Council funding by drawing together 30 research teams into a cohesive centre. These groups will ultimately be co-located in a purpose-designed 8000m2 facility to be constructed on the Cambridge Biomedical Research Campus. Platform technologies supported by a Centre grant will en able SCI to recruit and retain the most talented investigators and empower them to make ground-breaking advances in understanding stem cells and their medical applications. Fundamental research will focus at the molecular level on mechanisms of self-renewal, commitment, differentiation and reprogramming. Functional studies will address the role of stem cells in development, repair, ageing, physiology and pathologies including cancer. Disease-specific induced pluripotent stem cells will be exploi ted to unravel mechanisms of cellular pathogenesis and define drug targets. Strategies to mobilise endogenous stem cells for regeneration will be evaluated in animal models and in the clinic as will approaches based on cell transplantation. The Institute will provide comprehensive training in embryonic and adult stem cell biology and will seek, and offer unique opportunities for, bioindustry interaction and collaboration.

Amount: £1,263,038
Funder: The Wellcome Trust
Recipient: University of Cambridge

High speed super-resolution imaging with the OMX microscope. 09 Mar 2011

The imaging of fluorescent proteins in living cells has proved a powerful approach in cell biology, but many processes cannot be visualised because of the limited sensitivity and resolution of current microscopes. We seek funding for an OMX imaging system that overcomes these limitations. The OMX has a simplified light path that makes it much more sensitive than standard microscopes, and is configured to image three wavelengths simultaneously. These increase the speed of time-lapse imaging by an order of magnitude, allowing the detection of faint, fast-moving fluorescent objects that are otherwise invisible. The greater sensitivity also allows the use of lower levels of illumination, which reduces photo-toxicity and photo-bleaching for long-term time-lapse imaging of light-sensitive samples. Another major innovation is the use of structured illumination to break the diffraction limit, doubling resolution to 110nM. The OMX can perform super-resolution imaging deep inside cells at several frames/second (unlike other super-resolution microscopes), and can therefore reveal dynamic features of subcellular structure at a new scale. This microscope will be a shared resource for all cell biologists in Cambridge, and will be used to investigate topics such as mRNA trafficking, neuronal polarity, the spindle checkpoint and DNA damage foci.

Amount: £784,137
Funder: The Wellcome Trust
Recipient: University of Cambridge

High Resolution Imaging in 3D. 14 Oct 2010

The importance of microscopy in biomedical research cannot be overestimated, because it enables us to visualise the inner workings of the cell. We now know that in order for the cell to function properly, it needs to generate and maintain a number of different membrane compartments. This is achieved by packaging proteins and other molecules into vesicles that traffic from one compartment to another. The Robinson lab is investigating how different membrane proteins are packaged into the right kin ds of vesicles; the Buss lab works on the molecular motors that move the vesicles and organelles around in the cell; the Luzio lab investigates the docking and fusion of vesicles and organelles, in particular lysosomes; and the Griffiths lab focuses on how cytotoxic T lymphocytes (CTLs) orchestrate all their different types of trafficking machinery to kill target cells. Questions we will be addressing using the new microscopes include how different types of vesicles form in space and time, how t he motor protein myosin VI recruits its different partners in living cells, how organelles become tethered to each other prior to fusion, and how the immunological synapses of CTLs are formed.

Amount: £747,000
Funder: The Wellcome Trust
Recipient: University of Cambridge

An empirical base for understanding the early phase of the epidemiological transition: Short-term and spatial variations in infectious disease mortality in England 1600-1837. 08 Jun 2011

Omran's epidemiological transition from 'pestilences and famine' through a period of 'receding pandemics' has long been assumed to have been socio-economically, technologically and medically driven. In an English context limited success has been achieved in providing an effective epidemiological explanation for a diminution in the volatility of short-term death rates associated with infectious disease outbreaks. We will investigate to what extent different locations in England shared the sam e short term experience of mortality from c.1600 to 1837, as the nation transformed from a predominantly agrarian society to an increasingly urbanised and industrial one with an integrated transport system and growing international trading and migration flows. Using existing datasets of c.550 abstractions of individual parish burial registers (a 5 per cent sample of English parishes), we will consider whether mortality peaks and troughs coincided in different locations and whether synchronisati on increased over time. We will also aim to provide a firmer and detailed chronology for the divergence in the level and stability of adult and child mortality rates that is thought to have occurred in the early eighteenth century. We will trial similar analyses on later, Civil Registration-based data and develop more detailed age profiling using existing family reconstitutions.

Amount: £95,961
Funder: The Wellcome Trust
Recipient: University of Cambridge

The Charcot-Marie-Tooth diseases and associated defects in membrane transport. 25 Nov 2010

My overall goal is to understand the molecular mechanisms that underlie peripheral nerve myelination by Schwann cells, and the processes that become dysfunctional when disease-associated genes are mutated. I will do this by investigating Charcot-Marie-Tooth disease (CMT), the commonest inherited neuromuscular disorder. CMT4C is a severe progressive demyelinating neuropathy with apparent Schwann cell dysfunction associated with mutations in SH3TC2. My previous work investigating CMT4C has sugg ested that SH3TC2 plays a key role at the recycling endosome. I therefore plan to identify the proteins that interact with SH3TC2 in Schwann cells and to establish the effects of disease-causing mutations on these interactions. I will also develop functional assays to probe endocytic recycling and secretion in Schwann cells to determine the effect of SH3TC2 depletion, and the downregulation of other relevant proteins, on intracellular membrane transport. Furthermore, I will use Schwann cell/DR G (Dorsal Root Ganglion) neuron co-cultures to investigate the ability of SH3TC2-depleted cells to myelinate axons. Finally, as known myosin VI interacting proteins have been previously shown to influence myelination, I will establish the role of this unique actin-based motor protein in Schwann cells. By achieving a better understanding of the pathways involved in CMT, a common therapeutic target may emerge.

Amount: £796,349
Funder: The Wellcome Trust
Recipient: University of Cambridge

The biology of DEXI a novel candidate gene in autoimmune disease. 19 Jul 2011

The autoimmune diseases type 1 diabetes (T1D) and multiple sclerosis (MS) have a strong genetic basis, and recent genome-wide association studies have revealed many shared genetic risk variants, including the 16p13 region. Within this region, we have identified the DEXI gene, of unknown function and with no paralogue elsewhere in the genome as the most likely causal variant in autoimmune disease risk. The T1D and MS associated SNPs in the 16p13 region are eQTLs for DEXI expression in 2 independe nt monocyte data sets, and we have also shown their physical association with the DEXI promotor region by chromosome conformation capture. My future goal is to understand the biology of DEXI and its role in autoimmune disease pathogenesis. Key goals: 1. To evaluate changes in DEXI expression by qPCR in different stimulation conditions using cell lines, human monocytes and CD4+ cells 2. To develop a monoclonal antibody to DEXI to allow localisation of the protein within cells, quantificatio n of protein and to assist with the identification of binding partners of DEXI 3. To examine changes in immune cell gene-expression profiles by microarrray following over-expression and knockdown of the DEXI gene 4. To make recombinant DEXI and identify binding partners of this protein

Amount: £423,781
Funder: The Wellcome Trust
Recipient: University of Cambridge

Function and evolution of the atypical Notch ligands Dlk1 and Dlk2 during vertebrate development. 31 Aug 2011

Delta-like homologue 1 (Dlk1) is a vertebrate-specific atypical Notch ligand involved in development of multiple lineages in mouse. Genetic studies have shown it to be a key regulator within several pre and postnatal stem cell niches. Murine Dlk1 encodes soluble or membrane-bound protein isoforms depending on the presence of a juxtamembrane protein cleavage site, removed inalternatively spliced transcripts. Deciphering the signaling mechanisms of Dlk1 and the different functions of the Dlk1 isoforms has been very challenging in mouse. Zebrafish (Danio rerio) is an ideal model system to elucidate the fundamental aspects of Dlk1 function due to the relative ease and availability of molecular tools and techniques. In addition, Dlk1 in zebrafish is missing the juxtamembrane motif, whereas a closely related vertebrate-specific gene Dlk2, retains it, suggesting that zebrafish may use adifferent mechanism to produce membrane-bound and soluble Dlk, fulfilled by Dlk1 and Dlk2 respectively. Such proposed gene-specific functions make zebrafish a tractable model to decipher the specific roles of the secreted and

Amount: £155,658
Funder: The Wellcome Trust
Recipient: University of Cambridge